XML 31 R2.htm IDEA: XBRL DOCUMENT v3.3.0.814
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2015
Dec. 31, 2014
Current assets:    
Cash and cash equivalents $ 93,770 $ 160,203
Short-term investments 93,528 7,133
Accounts receivable 5,517 12,634
Deferred income taxes 7,517 0
Note receivable from Viking Therapeutics 5,547 0
Inventory 1,221 269
Capitalized expenses (Viking IPO) 0 2,268
Current debt issuance costs 847 809
Restricted investments 600 1,261
Other current assets 1,777 1,842
Total current assets 210,324 186,419
Deferred income taxes 206,423 0
Investment in Viking Therapeutics 31,826 0
Intangible assets, net 48,941 50,723
Goodwill 12,238 12,238
Commercial license rights 8,598 4,568
Long-term debt issuance costs 2,747 3,388
Property and equipment, net 355 486
Other assets 248 207
Total assets 521,700 258,029
Current liabilities:    
Accounts payable 3,143 7,698
Accrued liabilities 4,156 4,866
Current contingent liabilities 7,620 6,796
Current lease exit obligations 1,300 2,356
Other current liabilities 34 1,063
Total current liabilities 16,253 22,779
Long-term debt, net 202,951 195,908
Long-term contingent liabilities 7,589 8,353
Long-term lease exit obligations 0 934
Deferred income taxes 0 2,792
Long-term deferred revenue, net 2,083 2,085
Other long-term liabilities 643 770
Total liabilities $ 229,519 $ 233,621
Commitments and Contingencies
Stockholders' equity:    
Common stock, $0.001 par value; 33,333,333 shares authorized; 19,918,334 and 19,575,150 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively $ 20 $ 20
Additional paid-in capital 697,061 680,660
Accumulated other comprehensive income 5,558 4,953
Accumulated deficit (410,458) (659,315)
Total stockholders' equity attributable to Ligand Pharmaceuticals 292,181 26,318
Noncontrolling interests 0 (1,910)
Total liabilities and stockholders' equity $ 521,700 $ 258,029